To the editor,
A 77-year-old woman presented to the emergency department of a local hospital with nausea, dizziness, and light-headedness beginning 3 days earlier. Except for ramipril 5 mg and acetylsalicylate 100 mg daily, she was free of any medicine. She had hypertension for 17 years and an episode of deep venous thrombosis 3 years ago. Her blood pressure and pulse rate were 170/100 mm Hg and 35 bpm, respectively. Her physical examination was completely normal. However, on electrocardiogram there was third-degree atrioventricular block, which was thought to be responsible from the clinical scenario. She was then transferred to our hospital for further evaluation and treatment. She was admitted to the coronary care unit with the diagnosis of complete atrioventricular block. She was symptomatic, and her heart rate was sometimes decreasing to as low as 20 bpm, thus an emergency transvenous temporary pacemaker was introduced. Because she became immobile and had a deep venous thrombosis history, enoxaparin with the dose of 1 mg/kg of body weight every 12 hours was started. While we were investigating for any reversible cause of atrioventricular block, she developed progressive pancytopenia. On day 6, white blood cell count (WBC) had decreased from 8100 cells/µL at baseline to 3600 cells/µL, hemoglobin level had decreased from 12.5 to 9.4 g/dL, and the platelet count had decreased from 177 000 to 81 000 platelets/µL. The hematology consultant recommended, considering the peripheral smear was normal and the only medication change was the addition of enoxaparin, that enoxaparin be stopped and a sepsis work-up be done. Enoxaparin was switched with warfarin. Sepsis work-up results were negative. Blood parameters reached nadir 1 day after administration of enoxaparin ceased (WBC, 3100 cells/µL; hemoglobin, 8.5 g/dL; and platelet count, 33 000 platelets/µL). Then they started to increase spontaneously and reached to the pretreatment level 8 days after enoxaparin was discontinued. She was implanted with a permanent VVI pacemaker and discharged without any hemorrhagic or infectious complications.
The use of low-molecular-weight heparins (LMWHs) have become popular in the past 2 decades. Major advantages of them over unfractionated heparin are a lack of need of activated partial thromboplastin time monitoring and ease of application in an out of the hospital environment. Clinical trials revealed that LMWHs are at least as effective as unfractionated heparin and, yet, have fewer side effects in many disease conditions. 1-5 This is especially true for heparininduced thrombocytopenia, which is encountered much more commonly with unfractionated heparin use than with LMWHs. 3 Enoxaparin, an LMWH used to treat and prevent deep venous thrombosis, has been evaluated in several clinical trials. [1] [2] [3] Physicians use it in a very wide spectrum of clinical conditions. 4,5 Although it has advantages over unfractionated heparin, clinicians must be wary of its potential complications, which may sometimes be life-threatening. To our knowledge, previous reports of side effects of enoxaparin have described thrombocytopenia but not pancytopenia.
